{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:31:53Z","timestamp":1784057513809,"version":"3.55.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1408,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Routine, intermittent inotropic therapy (IIT) is still applied in advanced heart failure (HF) patients either as a bridge to definitive treatment or as a mean to improve quality of life (QOL), despite limited evidence to support its' use. Given recent reports of improved QOL and reduced HF hospitalization, with levosimendan compared with placebo in advanced HF patients, we aimed to assess the effects of switching a small group of milrinone-treated patients to levosimendan. This was performed as part of a protocol for changing our ambulatory HF clinic milrinone-based IIT to levosimendan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Single-centre study of consecutive ambulatory advanced HF patients that received \u22654 cycles of once-weekly milrinone IIT at our HF outpatient clinic, who were switched to levosimendan IIT. All patients had left ventricular ejection fraction \u226435%, elevated B-natriuretic peptide (BNP), and were in New York Heart Association Classes III\u2013IV despite maximally tolerated guideline directed medical therapy. Patients were evaluated using BNP levels, echocardiography, cardio-pulmonary exercise test, and HF QOL questionnaire before and after 4 weeks of levosimendan IIT. The cohort included 11 patients, 10 (91%) were male and the mean age was 76 \u00b1 12 years. After 4 weeks of levosimendan therapy, maximal O2 consumption improved in 8\/9 (89%) by a mean of 2.28 mL\/kg [95% CI \u22120.22\u20133.38, P = 0.05]. BNP levels decreased in 9\/11 (82%) levosimendan treated patients, from a median of 1015 ng\/L [261\u20131035] to 719 ng\/L [294\u2013739], (P &amp;lt; 0.01). QOL as measure by the EQ-5D-5L questionnaire improved in 8\/11 (82%) patients after levosimendan IIT, by a median of two points [95% CO \u22124.14\u20130.37, P = 0.09]. On echocardiography, peak systolic annular velocity (S') increased after levosimendan IIT by an average of 3 cm\/s [95% CI 0.16\u20132.10, P = 0.03].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small-scale study of ambulatory advanced HF patients, we observed improvements in right ventricular systolic function, maximal O2 consumption, and BNP after switching from milrinone to levosimendan based IIT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13807","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T04:38:05Z","timestamp":1643258285000},"page":"1487-1491","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intermittent Inotropic Therapy with Levosimendan vs. Milrinone in Advanced Heart Failure Patients"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3319-0336","authenticated-orcid":false,"given":"Assi","family":"Milwidsky","sequence":"first","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Frydman","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]},{"name":"Internal Medicine \u201cB\u201d at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Laufer-Perl","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sadeh","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Sapir","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Granot","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviram","family":"Hochstadt","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuba","family":"Korotetski","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Ketchker","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Topilsky","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Banai","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Havakuk","sequence":"additional","affiliation":[{"name":"Cardiology Department at the Tel-Aviv Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"2026012114170190300_ehf213807-bib-0001","first-page":"757","article-title":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis","volume":"6","author":"Nizamic","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"2026012114170190300_ehf213807-bib-0002","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ehf2.12114","article-title":"Quality of life and long-term mortality in patients with advanced chronic heart failure treated with intermittent low-dose intravenous inotropes in an outpatient setting","volume":"4","author":"Chernomordik","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026012114170190300_ehf213807-bib-0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2147\/IJGM.S62549","article-title":"Inotropes do not increase mortality in advanced heart failure","volume":"7","author":"Guglin","year":"2014","journal-title":"Int J Gen Med"},{"key":"2026012114170190300_ehf213807-bib-0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejheart.2006.04.012","article-title":"Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure","volume":"9","author":"Lilleberg","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026012114170190300_ehf213807-bib-0005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Com\u00edn-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114170190300_ehf213807-bib-0006","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","article-title":"Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial","volume":"8","author":"Mann","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/2\/1487\/65375733\/eschf_9_2_1487.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/2\/1487\/65375733\/eschf_9_2_1487.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:20:23Z","timestamp":1769023223000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/2\/1487\/8326220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":6,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,27]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13807","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"2021-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}